2020 Annual Meeting | C27 - Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

Date Saturday 04/25/20

Time 01:30 PM - 03:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Benjamin M. Greenberg, MD, FAAN

Topic(s) Neuro-rehabilitation

Learning Objectives Participants should be able to initiate a work up for acute and subacute myelopathy, initiate empiric treatment, and understand when to order comprehensive testing for vascular myelopathies. Participants will be able to differentiate classical transverse myelitis from acute flaccid myelitis and appreciate the therapeutic and prognostic implications of this differentiation.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
01:30 PM - 01:45 PM	Introduction	Introduction to Myelopathies Benjamin M. Greenberg, MD, FAAN
01:45 PM - 02:30 PM	Speaker	Inflammatory Myelopathies Kyle M. Blackburn, MD
02:30 PM - 03:15 PM	Speaker	Vascular Myelopathies Philippe Gailloud, MD
03:15 PM - 03:30 PM	Closing Remarks	Case Conclusions Benjamin M. Greenberg, MD, FAAN

Faculty Disclosures
Benjamin M. Greenberg, MD, FAAN	Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Husch Blackwell. Dr. Greenberg has stock in GenrAb. Dr. Greenberg has stock in Clene. The institution of Dr. Greenberg has received research support from Anokion. The institution of Dr. Greenberg has received research support from Regeneron. Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Philippe Gailloud, MD	Dr. Gailloud has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerenovus. Dr. Gailloud has received stock or an ownership interest from ArtVentive. The institution of Dr. Gailloud has received research support from Siemens Medical.
Kyle M. Blackburn, MD	Dr. Blackburn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.

��ɫ��

��ɫ��